PEAK6 Investments’s Esperion Therapeutics ESPR Stock Holding History

PEAK6 Investments’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-54,300	Closed	-$364K	–	4643
2022 Q3	$364K	Buy	+54,300	New	+$373K	﹤0.01%	3176

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PEAK6 Investments's ESPR Position: Q1 2020 in Review

PEAK6 Investments sold out of Esperion Therapeutics (ESPR) in Q1 2020, closing a stake of 1,177 shares — an estimated $70K sold.

PEAK6 Investments first reported a position in ESPR in Q1 2019 and held it in 4 quarters. The position peaked at $942K in Q2 2019. 165 funds tracked by Wall St. Rank hold ESPR as of Q1 2020.

PEAK6 Investments reported no remaining Esperion Therapeutics position as of Q1 2020 after selling out during the quarter.
PEAK6 Investments sold 1,177 Esperion Therapeutics shares in Q1 2020, an estimated $70K.
PEAK6 Investments first reported a position in Esperion Therapeutics in Q1 2019 and held it in 4 quarters.
PEAK6 Investments's Esperion Therapeutics position peaked at $942K in Q2 2019.
165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2020.

Based on PEAK6 Investments's 13F filing for Q1 2020, filed 14 May 2020.